Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) mice

International Journal of Oncology

Volumn 32, Issue 1, 2008, Pages 153-159

  Hamada, Kenji ^a,b   Monnai, Makoto ^a,c   Kawai, Kenji ^a   Nishime, Chiyoko ^a   Kito, Chika ^a   Miyazaki, Noriyuki ^d   Ohnishi, Yasuyuki ^a   Nakamura, Masato ^a,d,e   Suemizu, Hiroshi ^a  

^a CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^c Chugai Research Institute for Medical Science Inc   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKAI UNIVERSITY HACHIOJI HOSPITAL   (Japan)

Author keywords

Farnesyltransferase inhibitor; Human colon cancer; Liver metastasis model; NOD Shi scid IL2R nuul mice; NOG mice

Indexed keywords

ASPARTIC ACID; CH 4512600; GLYCINE; IRINOTECAN; MESSENGER RNA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL STRAIN HCT116; CODON; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; GENE EXPRESSION REGULATION; GENOTYPE; HUMAN; HUMAN CELL; IN VIVO STUDY; INOCULATION; LIVER METASTASIS; LOW DRUG DOSE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; POINT MUTATION; PRIORITY JOURNAL; RELIABILITY; STRUCTURE ACTIVITY RELATION;

EID: 38749083344     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.153     Document Type: Article

References (43)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Boyle P and Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann Oncol 16: 481-488, 2005.
3. Ballantyne GH and Quin J: Surgical treatment of liver metastases in patients with colorectal cancer. Cancer 71: 4252-4266, 1993.
4. Cromheecke M, De Jong KP and Hoekstra HJ: Current treatment for colorectal cancer metastatic to the liver. Eur J Surg Oncol 25: 451-463, 1999.
5. Biasco G and Gallerani E: Treatment of liver metastases from colorectal cancer: what is the best approach today? Dig Liver Dis 33: 438-444, 2001.
6. Ruers T and Bleichrodt RP: Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38: 1023-1033, 2002.
7. McCormick F: Signal transduction. How receptors turn Ras on. Nature 363: 15-16, 1993.
8. McCormick F: Activators and effectors of ras p21 proteins. Curr Opin Genet Dev 4: 71-76, 1994.
9. Barbacid M: Important Advances in Oncology. J.B. Lippincott, Philadelphia, pp3-22, 1986.
10. Gibbs JB: Ras C-terminal processing enzymes - new drug targets? Cell 65: 1-4, 1991.
11. Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ and Schlessinger J: BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell 75: 175-185, 1993.
12. Hancock JF, Magee AI, Childs JE and Marshall CJ: All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57: 1167-1177, 1989.
13. Casey PJ, Solski PA, Der CJ and Buss JE: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci USA 86: 8323-8327, 1989.
14. Reiss Y, Goldstein JL, Seabra MC, Casey PJ and Brown MS: Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides. Cell 62: 81-88, 1990.
15. Manne V, Roberts D, Tobin A, O'Rourke E, De Virgilio M, Meyers C, Ahmed N, Kurz B, Resh M and Kung HF: Identification and preliminary characterization of protein-cysteine farnesyltransferase. Proc Natl Acad Sci USA 87: 7541-7545, 1990.
16. Moores SL, Schaber MD, Mosser SD, Rands E, O'Hara MB, Garsky VM, Marshall MS, Pompliano DL and Gibbs JB: Sequence dependence of protein isoprenylation. J Biol Chem 266: 14603-14610, 1991.
17. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE and Der CJ: Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci USA 87: 3042-3046, 1990.
18. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE and Der CJ: Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992.
19. Venkatasubbarao K, Choudary A and Freeman JW: Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases. Cancer Res 65: 2861-2871, 2005.
20. Beaupre DM, McCafferty-Grad J, Bahlis NJ, Boise LH and Lichtenheld MG: Farnesyl transferase inhibitors enhance death receptor signals and induce apoptosis in multiple myeloma cells. Leuk Lymphoma 44: 2123-2134, 2003.
21. Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL and Joseph IB: Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models. Clin Cancer Res 11: 3045-3054, 2005.
22. Head J and Johnston SR: New targets for therapy in breast cancer: farnesyltransferase inhibitors. Breast Cancer Res 6: 262-268, 2004.
23. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, Chatfield LK, Gallicchio VS and Ahmed MM: Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 21: 7883-7890, 2002.
24. Head JE and Johnston SR: Protein farnesyltransferase inhibitors. Expert Opin Emerg Drugs 8: 163-178, 2003.
25. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T and Nakahata T: NOD/SCID/ gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100: 3175-3182, 2002.
26. + cells in nonobese diabetic/Shi-scid, IL-2 receptor gamma null mice. J Immunol 169: 204-209, 2002.
27. Miyakawa Y, Ohnishi Y, Tomisawa M, Monnai M, Kohmura K, Ueyama Y, Ito M, Ikeda Y, Kizaki M and Nakamura M: Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice. Biochem Biophys Res Commun 313: 258-262, 2004.
28. Dewan MZ, Watanabe M, Terashima K, Aoki M, Sata T, Honda M, Ito M, Yamaoka S, Watanabe T, Horie R and Yamamoto N: Prompt tumor formation and maintenance of constitutive NF-kappaB activity of multiple myeloma cells in NOD/SCID/gammacnull mice. Cancer Sci 95: 564-568, 2004.
29. Matsuura-Sawada R, Murakami T, Ozawa Y, Nabeshima H, Akahira J, Sato Y, Koyanagi Y, Ito M, Terada Y and Okamura K: Reproduction of menstrual changes in transplanted human endometrial tissue in immunodeficient mice. Hum Reprod 20: 1477-1484, 2005.
30. Ikoma N, Yamazaki H, Abe Y, Oida Y, Ohnishi Y, Suemizu H, Matsumoto H, Matsuyama T, Ohta Y, Ozawa A, Ueyama Y and Nakamura M: S100A4 expression with reduced E-cadherin expression predicts distant metastasis of human malignant melanoma cell lines in the NOD/SCID/gammaCnull (NOG) mouse model. Oncol Rep 14: 633-637, 2005.
31. null (NOG) mace. Int J Oncol 31: 741-751, 2007.
32. Kohl NE, Wilson FR, Mosser SD, Giuliani E, De Solms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP and Lee TJ: Protein farnesyltransferase inhibitors block the growth of rasdependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145, 1994.
33. Sun J, Qian Y, Hamilton AD and Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. Cancer Res 55: 4243-4247, 1995.
34. Zhang B, Prendergast GC and Fenton RG: Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 62: 450-458, 2002.
35. Feldkamp MM, Lau N, Roncari L and Guha A: Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res 61: 4425-4431, 2001.
36. Lantry LE, Zhang Z, Yao R, Crist KA, Wang Y, Ohkanda J, Hamilton AD, Sebti SM, Lubet RA and You M: Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Carcinogenesis 21: 113-116, 2000.
37. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (review). Int J Oncol 7: 413-421, 1995.
38. Tuzi NL, Venter DJ, Kumar S, Staddon SL, Lemoine NR and Gullick WJ: Expression of growth factor receptors in human brain tumours. Br J Cancer 63: 227-233, 1991.
39. Guha A, Feldkamp MM, Lau N, Boss G and Pawson A: Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 15: 2755-2765, 1997.
40. Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M and Ellis LM: Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9: 610-616, 2002.
41. Chen C, Pore N, Behrooz A, Ismail-Beigi F and Maity A: Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 276: 9519-9525, 2001.
42. Berra E, Pagès G and Pouysségur J: MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139-145, 2000.
43. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Shirasawa S, Sasazuki T and Kerbel RS: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 55: 4575-4580, 1995.